Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

2011767 citationsJournal Articlebronze Open Access

Authors

Maria De Santis · Kaiser-Franz-Josef-Spital

Joaquim Bellmunt · Kaiser-Franz-Josef-Spital

Graham M. Mead · Kaiser-Franz-Josef-Spital

J. Martijn Kerst · Kaiser-Franz-Josef-Spital

Michael Leahy · Kaiser-Franz-Josef-Spital

Pablo Maroto · Kaiser-Franz-Josef-Spital

Thierry Gil ·

Abstract

There were no significant differences in efficacy between the two treatment groups. The incidence of severe acute toxicities was higher for those receiving M-CAVI.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Multiple and Secondary Primary Cancers Urinary and Genital Oncology Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 2, pp. 191-199

DOI: 10.1200/jco.2011.37.3571

Field-Weighted Citation Impact: 21.22